Frazier Life Sciences Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Maze Therapeutics
MAZE
|
+$49.7M |
| 2 |
Dyne Therapeutics
DYN
|
+$20.6M |
| 3 |
RNAM
Avidity Biosciences
RNAM
|
+$16.4M |
| 4 |
Zai Lab
ZLAB
|
+$10.8M |
| 5 |
Mirum Pharmaceuticals
MIRM
|
+$10.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rhythm Pharmaceuticals
RYTM
|
+$66.1M |
| 2 |
Edgewise Therapeutics
EWTX
|
+$33.9M |
| 3 |
Oric Pharmaceuticals
ORIC
|
+$21.7M |
| 4 |
AnaptysBio
ANAB
|
+$20.8M |
| 5 |
Krystal Biotech
KRYS
|
+$16.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.79% |
| 2 | Miscellaneous | 0.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Eledon Pharmaceuticals
ELDN
$176M
| – | – |
-1,176,735
| Closed | -$4.85M | – |
|
52
DELISTED
89bio
ETNB
| – | – |
-1,000,000
| Closed | -$7.82M | – |
|
|
53
Edgewise Therapeutics
EWTX
$4.03B
| – | – |
-1,271,245
| Closed | -$33.9M | – |
|
54
Pliant Therapeutics
PLRX
$56.4M
| – | – |
-1,120,803
| Closed | -$14.8M | – |
|
Similar funds
Frazier Life Sciences Management's Q1 2025 Portfolio in Review
As of Q1 2025, Frazier Life Sciences Management held 54 positions worth $2.19B, down 9.2% from $2.41B the previous quarter. Its ten largest holdings account for 70% of the portfolio.
Frazier Life Sciences Management withdrew a net $84.5M in Q1 2025, closing 7 positions and reducing 8 holdings. Its most notable exit was Edgewise Therapeutics, an estimated $33.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.
Against the trend, Frazier Life Sciences Management opened a new position in Maze Therapeutics worth $45.5M.
- Frazier Life Sciences Management's largest Q1 2025 buy was Maze Therapeutics: 4,129,001 shares worth $45.5M.
- Frazier Life Sciences Management added most to Mirum Pharmaceuticals in Q1 2025, an estimated $10.6M increase.
- Frazier Life Sciences Management's biggest Q1 2025 reduction was Rhythm Pharmaceuticals, cutting an estimated $66.1M.
- Frazier Life Sciences Management fully exited Edgewise Therapeutics in Q1 2025, selling an estimated $33.9M.
- Frazier Life Sciences Management's ten largest holdings make up 70% of its $2.19B portfolio in Q1 2025.
- Frazier Life Sciences Management opened 4 new positions and closed 7 in Q1 2025.
- Frazier Life Sciences Management's portfolio value fell 9.2% quarter-over-quarter to $2.19B.
Based on Frazier Life Sciences Management's 13F filing for Q1 2025, filed 15 May 2025.